Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)
Closed Posted
- Opportunity number
- RFA-AR-25-014
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.233 National Center on Sleep Disorders Research
- 93.837 Cardiovascular Diseases Research
- 93.838 Lung Diseases Research
- 93.839 Blood Diseases and Resources Research
- 93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- 93.867 Vision Research
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- Higher Education Inst. (Public)
- City/Township Governments
- Higher Education Inst. (Private)
- Small Businesses
- Independent School Districts
- State Governments
- Special District Governments
- For Profit Organizations
- Public or Indian Housing Auth.
- Other
- County Governments
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is seeking applications for the Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials, a limited competition grant focusing on advancing regenerative medicine research using adult stem cells. This cooperative agreement opportunity, authorized through the 21st Century Cures Act, will utilize the UH3 activity code and is designed to support clinical trials in regenerative medicine. Eligible applicants include a wide range of entities such as tribal governments, nonprofits, higher education institutions, small businesses, and state and local government organizations. Investigators who have been previously funded through the Regenerative Medicine Innovation Project are particularly encouraged to apply. The evaluation criteria will likely focus on scientific merit, technical approach, investigator qualifications, research facilities, budget appropriateness, and alignment with program objectives.
While specific award amounts are not detailed in the grant opportunity, the funding will be provided through a cooperative agreement mechanism, suggesting collaborative research between the funding agency and selected researchers. The grant opportunity is currently in a forecast stage, with applications not yet being solicited, providing potential applicants time to develop meaningful collaborations and responsive projects. The posted date is June 9, 2025, with a due date of December 9, 2025. The research will be conducted at the recipient organizations' facilities, with a focus on advancing scientific understanding and potential clinical applications of adult stem cell research. The project is part of a broader NIH initiative spanning multiple research domains, including Arthritis, Musculoskeletal and Skin Diseases Research, Lung Diseases Research, Cardiovascular Diseases Research, and Translation and Implementation Science Research.
Synopsis
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Required)
Files
| File | Type | Posted |
|---|---|---|
| RFA-AR-25-014-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity